Pfizer vaccine has 91% efficacy for up to six months, trial shows

Findings based on two doses three weeks apart are first to show shot remains effective for many months

The coronavirus vaccine developed by Pfizer and its German partner BioNTech protects against symptomatic Covid for up to six months, an updated analysis of clinical trial data has found.

In a statement released on Thursday, the companies reported efficacy of 91.3% against any symptoms of the disease in participants assessed up to six months after their second shot. The level of protection is only marginally lower than the 95% achieved soon after vaccination.

Continue reading…

Leave a Reply

Your email address will not be published. Required fields are marked *